SCHEMBL29192548

SCHEMBL29192548

CS(=O)(=O)c1ccc2cncc(Br)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
PTGS2 P35354 2/20 0.38
NQO2 P16083 1/20 0.36
MTNR1A P48039 1/20 0.36
MTNR1B P49286 1/20 0.36
CDK5 Q00535 3/20 0.36
CDK5R1 Q15078 2/20 0.36
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 2/20 0.36
CRHR1 P34998 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
G6PD P11413 1/20 0.34
IDE P14735 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SCD O00767 1/20 0.34
AURKA O14965 1/20 0.34
ROCK2 O75116 1/20 0.34
CHEK2 O96017 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29192477 0.80 G6PD (0.45) CCNCCDK8PTGS2NQO2MTNR1A
SCHEMBL17437243 0.80 LMNA (0.42) CCNCCDK8PTGS2ROCK2ROCK1
SCHEMBL30032674 0.80 G6PD (0.45) CCNCCDK8PTGS2NQO2MTNR1A
SCHEMBL29923537 0.73 CYP1A2 (0.41) RAB9A
SCHEMBL17981072 0.73 CYP1A2 (0.41) RAB9A
SCHEMBL29192439 0.72 CDK5 (0.39) CCNCCDK8NQO2MTNR1AMTNR1B
SCHEMBL3950620 0.72 PTGS2 (0.43) PTGS2NQO2MTNR1AMTNR1BAKR1C3
SCHEMBL18105506 0.71 EGFR (0.46) KDR
SCHEMBL30797366 0.70 IMPDH2 (0.45) PTGS2CDK5AKR1C3AKR1C2SCD
SCHEMBL12567839 0.70 PIK3CD (0.45) PTGS2AKR1C3AKR1C2SCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117651699-A Compounds and compositions for the treatment of coronavirus related diseases 诺华股份有限公司 2024-03-05 CN disclosed
WO-2022224223-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES NOVARTIS AG (CH) 2022-10-27 WO disclosed